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Abstract
Objective: The objective of this selective EBM review is to determine whether or not Botox is a
safe and effective treatment to reduce symptoms of depression? Study Design: The review is
based on three Randomized Control Trials that were double-blind and placebo controlled clinical
trials. Data Source: All articles were researched and found using PubMed and Medline. The
articles were selected based on the relevance to my clinical question and if the articles included
patient oriented outcomes (POEMS).
Outcomes Measured: The outcomes were measured by the improvement of depressive symptoms
(sleep disturbances, suicide ideations, change in
appetite/weight/concentration/energy/guilt/interests) and improvement in scores from the
Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (17
and 21), Beck Depression Inventory (BDI) and Patient Health Care Questionnaire-9.
Results: In the study by Finzi et al. (2013), they found statistical evidence (p <0.001) that Botox
improved symptoms of Major Depressive Symptoms. The evidence revealed that 52% of patients
at 6 weeks showed signs of improvement compared to the placebo group whom showed a 15%
improvement of symptoms. A study by Magid et al. (2014) also found statistical evidence
(p<0.001) that treatment with Botox did improve symptoms of Major Depressive Disorder
(MDD). The study showed that 55% of the patients who received Botox responded to treatment
and had decreased symptoms with 0% of the placebo group showing any reduction in symptoms.
A study by Wollmer et al. (2012) also supported the previous evidence with statistical findings
(p=0.002) that MDD symptoms improved with the use of Botox. Patients had reduced symptoms
on average of 47% with the use of Botox compared to the placebo group whom had a decrease in
9.2% of their symptoms.
Conclusion: The results from all three Randomized Control Trials proved that Botox is a safe
and effective treatment to reduce symptoms of depression.
Key Words: Botulinum Toxins, Depression
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INTRODUCTION
Major Depressive Disorder (MDD) is an illness that affects 16% of the US population,
more than 350 million people worldwide, and is a leading cause of disability internationally.2 In
the most recent surveys, MDD has the highest lifetime prevalence of any psychiatric disorder
and patients are at an increased risk for additional comorbid disorders such as alcohol abuse,
panic disorder, obsessive compulsive disorder and social anxiety.8
Although there was no exact estimate available for annual health care visits, we know
that depression affects more than 15 million American adults, or about 6.7 percent of the U.S.
population age 18 and older in a given year.7 The economic burden of depression was estimated
at $83.1 billion in 2000 in the United States.5 For employed and treated patients, incremental
direct costs of health care services were $5,707 per MDD patient in 2005, increasing by 5% in
2010 to $5,988.5
The exact etiology of MDD is not clearly defined; however, it is thought to be due to
either long term effects of chronic stress on the brain from increased cortisol and CRH or from a
decrease in monoamines (dopamine, serotonin, norepinephrine) causing the brain to up-regulate
monoamine receptors leading to depression.6 The diagnosis of MDD is obtained through a good
clinical history.8 The diagnosis is based on the patient having at least 5 symptoms (one must be
depressed mood or anhedonia) for 2 weeks.6 The symptoms include: sleep disturbance, feeling of
guilt, decreased energy, decreased concentration, appetite change, psychomotor agitation, and
suicidal ideations.6
The most effective intervention for achieving remission and preventing relapse is
medication, but combined treatment, incorporating psychotherapy to help the patient cope with
decreased self-esteem and demoralization, improves outcomes.6 The classes of antidepressant
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medications are serotonin selective reuptake inhibitor (SSRI), serotonin norepinephrine reuptake
inhibitor (SNRI), norepinephrine dopamine reuptake inhibitor (NDRI), tricyclic antidepressant
(TCA), and monoamine oxidase inhibitor (MAOI). The available antidepressants do not differ in
overall efficacy, speed of response, or long-term effectiveness, however, they do differ in their
pharmacology, drug-drug interactions, short- and long-term side effects, likelihood of
discontinuation symptoms and ease of dose adjustment.8 A rational approach to selecting which
antidepressant to use involves matching the patient’s preference and medical history with the
metabolic and side effect profile of the drug.6
Troubling side effects from the use of antidepressants, such as decreased libido,
anorgasmia, insomnia and nausea, are a major reason why patients discontinue treatment and
subsequently relapse.1 A relevant proportion of patients do not sufficiently improve with
medication management and psychotherapy and are often left with fewer therapeutic options.2
The use of Ontabotulinumtoxin A (Botox) may be used as an adjunct to anti-depressant
medications or psychotherapy for the treatment of depressive symptoms.
The theories behind why Botox may be effective for treatment of MDD and its
mechanism of action is through the facial feedback hypothesis.1 The hypothesis suggests that
facial expression influences emotional perception; producing an expression that is characteristic
of a particular emotion can lead to experiencing an emotion (eg, smiling can lead to happiness,
scowling can lead to anger).2 One study showed that mimicking facial expressions of anger or
fear, even with no emotional valence attached to the expression, can lead to significant changes
in heart rate and temperature.2 Injecting Botox into the muscles responsible for expression of
anguish or sadness may potentially decrease the patients experience of feelings.1,2 Botox
reversibly blocks acetylcholine release from neuronal axons into the synapse, inhibiting
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neuromuscular transmission.2 If the facial feedback hypothesis is correct, by injecting Botox into
the corrugator and procerus muscles, it will reversibly inhibit frown facial expressions and have
the capability of propagating or enhancing sad and depressed feelings.1
OBJECTIVE
The objective of this selective EBM review is to determine whether or not Botox is a safe
and effective treatment to reduce symptoms of depression.
METHOD
The studies that are evaluated in this systemic review are three randomized control trials that
were double-blind with placebo controlled trials. The articles were researched through PubMed
and Medline and all three articles were published in English between 2012 and 2014. The
keywords that were searched in PubMed and Medline were “Botulinum Toxins” and
“Depression”. Articles were selected based on the relevance to my clinical question and if the
articles included patient oriented outcomes (POEMS).
The criteria used for the selection of each study was based on the population study,
intervention, comparisons group and the outcomes of each study. The population being studied
in the three studies included men and women between the age of 18 and 65 with an ongoing
diagnosis of MDD. Wollmer et al.3 varied in that it only used patients between the ages of 25 and
65.
The intervention being used in all three studies was Ontabotulinumtoxin A, 29U for women
and 39U for men. For women, 7U was injected into the procerus muscle and 6U was injected
bilaterally to the medial part of the corrugator muscles and 5U bilaterally to the middle part of
the corrugator muscle. For men, 9U was injected into the procerus muscle and 8U was injected
bilaterally to the medial part of the corrugator muscles and 7U bilaterally to the middle part of
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the corrugator muscle. The Botox was compared to the use of a placebo, 0.9%NaCl solution,
which used the same number of units injected into the same locations as the Botox.
The inclusion criteria for all three studies included randomized control trials that were
double-blind, all included relevant POEMS, all patients were over 18 years old, patients had an
ongoing diagnosis of MDD, and all studies evaluated the efficacy of Botox on MDD. The
exclusion criteria included patients that were under the age of 18, had an active substance abuse
problem, had an unstable medical condition or had previous Botox treatments. The statistical
analyses were reported by p-values, NNT, RBI and ABI. Table 1 represents the demographics
and characteristics of each study.
OUTCOMES MEASURED
All three studies were measuring outcomes by improvement of major depressive
symptoms and improvement of scores on self-rating questionnaires. Finzi et al. measured their
outcomes based on the Montgomery and Asberg Depression Rating Scale (MADRS) and Beck
Depression Inventory (BDI) which is filled out by the patient and the Clinical Global Impression
(CGI) which is filled out by a clinician.1 Magid et al. measured their outcomes primarily with
patient questionnaires such as the Patient Health Care Questionnaire-9, BDI and 21-item
Hamilton Depression Rating Scale.2 Wollmer et al. measured outcomes using the 17-item
Hamilton Depression Rating Scale, BDI, CGI scale and four-point clinical severity score for
Glabellar Frown Lines.3
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Table 1: Demographics and characteristics of included studies
Study
Type
#
Age Inclusion
Exclusion Criteria
Pts
Criteria
Finzi
Double 85 18- Outpatient men Patients with
(2013)1
Blind
65
and women
another Axis I
RCT
aged 18-65 with disorder, substance
a DSM-IV
abuse history, illicit
diagnosis of
drug use, attempted
MDD. Patients
suicide in past 6
must have
months, unstable
MADRS score
medical condition,
>26 and a
treated with OBA
Clinical Global in past 12 months,
impression
change in
Severity >4.
medication regimen
Magid
Double 30 18- Men and
Active substance
(2014)2
Blind
65
women ages 18- abuse, bipolar
RCT
65 with a
disorder,
history of MDD pregnancy, unstable
for at least 6
medical condition,
months as
previous Botox
defined by
treatment, treatment
DSM-IV
with > 3
criteria. Patients psychotropic
must have
medications,
scored a 14 or
another axis H
greater on the
comorbidity
21-Item
Hamilton
Depression
Rating Scale
Wollmer Double 30 25- Men and
Psychotic
(2012)3
Blind
65
women age 25- symptoms, suicide
RCT
65 with a
tendency, untreated
diagnoses of
depressed, another
on-going MDD DSM-IV axis I
and taking 1-2
diagnosis,
antidepressants personality
for at least 4
disorder, severe
weeks and have PMS/PMDD,
a moderate to
regular migraines,
severe vertical
contraindications of
glabellar line.
Botox, previous
treatment with
Botox

W/
D
0

0

0

Intervention
Single
injection of
Ontabotulin
umtoxinA
vs. placebo
group
receiving
0.9% NaCl
(29U for
women and
39U for
men)
Single
injection of
Ontabotulin
umtoxinA
vs. placebo
group
receiving
0.9% NaCl
(29U for
women and
39U for
men)

Single
injection of
Ontabotulin
umtoxinA
vs. placebo
group
receiving
0.9% NaCl
(29U for
women and
39U for
men)
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RESULTS
All three randomized control double-blind trials in this systemic review used the methods
previously described to determine the efficacy of using Botox to treat MDD in comparison to a
placebo of 0.9% NaCl over a six-week period.
In the study by Finzi et al.1, 74 subjects were randomly selected in the double-blind
study, 33 in the Onabotulinumtoxin A group (OBA) and 41 in the placebo group with very minor
demographic differences between the OBA group and placebo group. The participants were
required to complete initial MADRS questionnaires. The participants were followed up with the
same questionnaires at week 3 and week 6 to determine the efficacy of Botox. At week 6, 52% of
the participants in the OBA group had improved depressive symptoms compared to the 15% in
the placebo group. The two groups were compared statistically by calculating a p-value of
<0.001. Since the p-value is < 0.5 the treatment is statistically significant. Table 3 outlines the
mean MADRS scores between the OBA group and the placebo group. The table outlines a
significant decrease in scores in the OBA group at week 0 (31.6) and week 6 (16.9) in
comparison to a slighter decrease in the placebo group at week 0 (31.2) and week 6 (24.6).
Table 2: Mean MADRS scores over time
OBA
Placebo

Week 0
31.6
31.2

Week 3
18.9
24.9

Week 6
16.9
24.6

In the Magid et al.2 study, there were 30 participants enrolled with 11 patients receiving
Onabotulinumtoxin A (BTA group) and 19 in the placebo group. Participants were monitored at
week 0, week 6, week 12 and week 24. This study included a crossover at week 12, however,
analysis was given for the initial 6 weeks then again after the crossover at week 24. In an attempt
to compare equivalent data, only the data from week 6 of each trial was used in this systemic
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review. At week 6, the response rate for BTA group was 55% and 0% for the placebo group. The
study found statistical evidence (p <0.001) that treatment with Botox did improve symptoms of
MDD.
In the Wollmer et al. study, there were 30 participants divided equally between the Botox
group and the placebo group. After 6 weeks of treatment, the Botox recipients’ symptoms were
reduced by 47.1% and the placebo by 9.2%. The study also supported previous evidence with
statistical findings (p=0.002) that MDD symptoms improve with the use of Botox.
Dichotomous data was used in all three studies. The Relative Benefit Increase (RBI),
Absolute Benefit Increase (ABI) and Numbers Needed To Treat (NNT) were calculated for all
three studies to determine the efficacy of Botox after six weeks of treatment. The data can be
found in Table 3. The NNT for all three studies shows that for every 2-3 patients treated with
Botox, one more will have benefit of treatment from Botox and relief of symptoms at six weeks
compared to the control group.
Table 3: Efficacy of Onabotulinumtoxin A in MDD symptoms at six weeks
CER

EER

RBI

ABI

NNT

Finzi et al.

15%

52%

71.15%

37%

2.7

Magid et al.

55%

0%

100%

55%

1.8

Wollmer et. al

9.2%

47.1%

80.9%

37.9%

2.6

Safety and tolerability was evaluated in the Finzi et al. and Wollmer et al. study. Table 4
shows the analysis of safety and tolerability of Botox and the placebo (NaCl 0.9%) in both
studies by calculating the Numbers Needed To Harm (NNH). In the Finzi et. al study the NNH
was -7.5 meaning that for every 7.5 patients exposed to the treatment, 1 fewer will develop an
adverse reaction compared to the control group. Only 3 adverse reactions occurred during the
study and 2 of the 3 occurred in the placebo group. In the placebo group one patient experienced
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vivid dreams and headaches while the second participant experienced headaches. In the
experimental group only one patient complained of headaches. In comparison, the Wollmer et al.
study had a NNH of -50 meaning that for every 50 patients treated with Botox, 1 fewer will
develop an adverse reaction compared to the control group. The main adverse effects in this
study included short episodes of headaches during the first few weeks of trial and occurred in
both the experimental and placebo group. There were no adverse reactions noted or evaluated in
the Magid et al. study.
Table 4: Safety and Tolerability of Botox vs Nacl 0.9% injection
Finzi et al.

CER
40%

EER
26.7%

RRI
-33%

ARI
-13.3%

NNH
- 7.5

Wollmer et. al

5%

3%

-0.4

-2

- 50

DISCUSSION
Botox is currently FDA approved for many conditions in adults such as chronic
migraines, upper limb spasticity, cervical dystonia, axillary hyperhidrosis, blepharospasm, and
strabismus.9 The contraindications to use of Botox are any hypersensitivity reactions or infection
at the site of injection. There are many adverse reactions with the use of Botox for other
conditions that range from non-life threatening such as headaches to life threatening such as
death. For example, Botox used for cervical dystonia most commonly causes an adverse reaction
of dysphagia but can also weaken accessory muscles that are necessary for adequate ventilation.9
If these muscles were to become weakened and the use of Botox was continued patients could
develop swallowing or breathing difficulties ultimately leading to death.9 The three studies
evaluated in this systemic review resulted in only non-life threatening adverse reactions, most
notably headaches.
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There were many limitations noted about all three studies. All three studies included a
small sample size of either 30 or 85 participants which may not provide enough sufficient
evidence to represent the true effectiveness of Botox in the MDD population. All three studies
were also female dominant with 93% of the Finzi et al. participants, 90% of the Magid et al.
participants and 78% of the Wollmer participants being female. Having a majority of the
participants being female does not provide any statistical analysis of effectiveness based on
gender. In addition, all three studies used Botox as an adjunct therapy to antidepressants or
psychotherapy and not as monotherapy.
CONCLUSION
Based on the systemic review, Botox is a safe and effective treatment to reduce the
symptoms of depression; however, it is not proven if Botox is an effective treatment as
monotherapy to reduce the symptoms of depression. All three studies showed significant
improvement of MDD symptoms with the use of Botox in the experimental group versus the
controlled group in a six-week period.
Future studies need to evaluate the use of Botox as monotherapy. This would allow the
treatment to be cost effective and patients would be more compliant as they would not have to
remember to take a medication every day. Future studies should also consider evaluating the
subjects for a longer duration to be able to provide adequate information on the length of time
each injection could potentially last. Additionally, more research should be done to evaluate the
potential long-term side effects from the use of Botox as continual therapy.
In conclusion, the systemic review proved that Botox is a safe and effective treatment to
reduce the symptoms of depression; however, continued research should be done to evaluate the
use of Botox as monotherapy and as long-term treatment.
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